Australian biotech market watch 05/03/10
Friday, 05 March, 2010
Not even an interest rate rise could put a dampener on the stock market this week, with the All Ordinaries up by 125 points, or 2.7 per cent, from Monday.
In contrast, the life sciences index has been a little more turbulent, slipping through to Thursday before a rebound in trading this morning to 8,733.
The lion's share of the rebound is due to the biotech gorilla, CSL (ASX:CSL), bumping up 66c, or 1.9 per cent, to $35.45, following news that CSL's subsidiary, CSL Behring, has been given the go ahead by the US Food and Drug Administration to market a new blood plasma product.
ResMed (ASX:RMD) also saw an 8c lift to $6.60.
The rest of the market has been relatively steady, although Primary Health Care did take an 11c dip to $4.15.
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
Alliance seeks to boost regional capacity in clinical trials
Launched this week, the Barwon Health–Deakin University Clinical Trials Alliance is...
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
